Most Recent Articles by Bryant Furlow
Data can be used to target the development of new drugs for treating squamous cell carcinomas.
Developed in Cuba, the TG4010 and CIMAvax-EGF vaccines are undergoing clinical study in the US.
Annual lung cancer screenings using low-dose computed tomography among high-risk individuals remain "low and unchanged."
Immune checkpoint inhibition with nivolumab is associated with durable clinical responses and a 16% 5-year survival rate among heavily pretreated patients with advanced non-small cell lung cancer.